SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but critical for productive class switch recombination

Estelle Vincendeau; Wenming Wei; Xuefei Zhang; Cyril Planchais; Wei Yu; Hélène Lenden-Hasse; Thomas Cokelaer; Juliana Pipoli da Fonseca; Hugo Mouquet; David J. Adams; Frederick W. Alt; Stephen P. Jackson; Gabriel Balmus; Chloé Lescale; Ludovic Deriano

doi:10.1038/s41467-022-31287-3

Nature Communications (Jun 2022)

SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but critical for productive class switch recombination

Estelle Vincendeau,
Wenming Wei,
Xuefei Zhang,
Cyril Planchais,
Wei Yu,
Hélène Lenden-Hasse,
Thomas Cokelaer,
Juliana Pipoli da Fonseca,
Hugo Mouquet,
David J. Adams,
Frederick W. Alt,
Stephen P. Jackson,
Gabriel Balmus,
Chloé Lescale,
Ludovic Deriano

Affiliations

Estelle Vincendeau: Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit
Wenming Wei: Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit
Xuefei Zhang: Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine at Boston Children’s Hospital, Department of Genetics, Harvard Medical School
Cyril Planchais: Institut Pasteur, Université de Paris, INSERM U1222, Laboratory of Humoral Immunology
Wei Yu: Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit
Hélène Lenden-Hasse: Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit
Thomas Cokelaer: Institut Pasteur, Plate-forme Technologique Biomics, Centre de Ressources et Recherches Technologiques
Juliana Pipoli da Fonseca: Institut Pasteur, Plate-forme Technologique Biomics, Centre de Ressources et Recherches Technologiques
Hugo Mouquet: Institut Pasteur, Université de Paris, INSERM U1222, Laboratory of Humoral Immunology
David J. Adams: Wellcome Trust Sanger Institute
Frederick W. Alt: Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine at Boston Children’s Hospital, Department of Genetics, Harvard Medical School
Stephen P. Jackson: Wellcome Trust/Cancer Research UK Gurdon Institute, Department of Biochemistry, University of Cambridge
Gabriel Balmus: UK Dementia Research Institute at University of Cambridge, Department of Clinical Neurosciences, University of Cambridge
Chloé Lescale: Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit
Ludovic Deriano: Institut Pasteur, Université Paris Cité, INSERM U1223, Équipe Labellisée Ligue Contre Le Cancer, Genome Integrity, Immunity and Cancer Unit

DOI: https://doi.org/10.1038/s41467-022-31287-3
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 16

Abstract

Read online

SHLD1, as a component of the Shieldin (SHLD) complex, mediates DNA repair via non-homologous end-joining (NHEJ), an essential process during lymphocyte development. Here the authors show that SHLD1 is actually dispensable for lymphocyte development and V(D)J recombination, but is essential for class-switching recombination in activated B cells.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal